Coherus Oncology Inc (CHRS)

SG&A Expenses

$20.95M

Quarterly · Period ending: · USD

CHRS logo

CHRS SG&A Expenses

Latest reported$20.95M
CHRS Quarterly SG&A Expenses ($1.29M → $20.95M)
High-resolution chart · PNG

CHRS sg&a expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Coherus Oncology Inc SG&A Expenses — Quarterly (USD)
Period endingSG&A Expenses (USD)
20,954,000
23,104,000
23,609,000
22,831,000
26,039,000
26,025,000
41,297,000
34,744,000
35,165,000
40,232,000
49,494,000
48,224,000
45,144,000
49,153,000
53,621,000
44,831,000
51,276,000
48,753,000
50,052,000
39,925,000
40,345,000
39,391,000
37,693,000
31,984,000
34,052,000
35,350,000
36,070,000
31,828,000
36,456,000
32,683,000
33,840,000
25,369,000
18,391,000
16,577,000
14,978,000
13,989,000
23,533,000
18,803,000
15,294,000
13,645,000
11,260,000
11,398,000
10,972,000
10,166,000
8,817,000
6,091,000
6,186,000
3,979,000
3,978,000
3,421,000
2,497,000
2,355,000
1,324,000
1,289,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.